Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
What's Going On With Viking Therapeutics Stock On Wednesday? Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Amgen Expands Development Plans For Highly Anticipated Obesity Drug Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
